AIM ImmunoTech Files 8-K for Material Agreement
Ticker: AIM · Form: 8-K · Filed: Jul 31, 2025 · CIK: 946644
Sentiment: neutral
Topics: material-agreement, 8-K, corporate-filing
TL;DR
AIM ImmunoTech signed a big deal, filing an 8-K on 7/30/25.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on July 30, 2025, reporting the entry into a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and headquartered in Ocala, Florida.
Why It Matters
This filing indicates a significant new contract or partnership for AIM ImmunoTech, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new opportunities but also potential risks and obligations for the company.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- HemispherX Biopharma Inc. (company) — Former company name
- July 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Ocala, FL (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by AIM ImmunoTech Inc.?
The filing states that AIM ImmunoTech Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 30, 2025.
What was AIM ImmunoTech Inc. formerly known as?
AIM ImmunoTech Inc. was formerly known as Hemispherx Biopharma Inc.
In which state is AIM ImmunoTech Inc. incorporated?
AIM ImmunoTech Inc. is incorporated in Delaware.
What is the business address of AIM ImmunoTech Inc.?
The business address of AIM ImmunoTech Inc. is 2117 SW Highway 484, Ocala, FL 34473.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 31, 2025 regarding AIM ImmunoTech Inc. (AIM).